PrecivityAD2 is a blood test that helps doctors check for Alzheimer's-related brain changes during a full memory evaluation. For families facing younger-onset Alzheimer's, it adds a lab clue to the clinical workup, not a standalone diagnosis. According to the Alzheimer's Association, the test was cleared to aid diagnosis in adults age 40 and older with cognitive symptoms who are already being evaluated, as described in the Association's clearance announcement. Younger-onset Alzheimer's affects people under 65, a time when work, parenting, and finances are often still in full swing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the test measure?
- Who is it for, and who is it not for?
- How accurate is it?
- What can younger-onset families do next?
What does the test measure?
PrecivityAD2 measures blood proteins linked to Alzheimer's pathology. According to the Mayo Clinic Laboratories report, it uses immunoprecipitation plus LC-MS/MS mass spectrometry to quantify Aβ42, Aβ40, p-tau217 and np-tau217, then combines two ratios into an Amyloid Probability Score 2, described in the laboratory's test overview. Aβ42/40 reflects amyloid buildup.
Percent p-tau217 reflects tau changes tied to amyloid. The APS2 score combines them into one result. A doctor reads that score alongside history, exams, and cognitive testing.
Who is it for, and who is it not for?
The cleared use is narrow. C2N Diagnostics states the test must be used with clinical assessment by professionals experienced in cognitive-impairment evaluation to identify amyloid pathology, as explained in the company's clearance statement. It is for adults with signs of cognitive impairment who are undergoing evaluation. It is not screening for people without symptoms.
It is not a home test or a final answer by itself. For younger families, the age floor matters. FixFirst Health notes PrecivityAD2 is cleared down to age 40, while two other cleared blood tests were limited to 55 and older. A 48-year-old with ongoing memory concerns fits the age question better than before.
How accurate is it?
In an independent validation in people with cognitive impairment, APS2 showed strong agreement with amyloid PET scans. According to the Nature Communications validation study, the prespecified cutoff showed 91 percent accuracy, 90 percent sensitivity, 92 percent specificity, 93 percent positive predictive value and 88 percent negative predictive value, reported in the peer-reviewed validation study. An earlier validation cohort reported lower numbers, around 88 percent accuracy and sensitivity and about 89 percent specificity. Performance shifts with disease prevalence in the tested group.
A result still needs clinical judgment, and follow-up testing may be needed. The Alzheimer's Association 2025 blood-biomarker guideline sets performance bars for triage and confirmatory uses. Families can ask where this result falls for their case. A clear question is whether PET or spinal-fluid testing is still advised.
What can younger-onset families do next?
Start with a clinician experienced in memory disorders. Bring a timeline of changes, work effects, medications, sleep issues, mood changes, and family observations. Ask whether blood-biomarker testing fits the current evaluation.
Use these steps at the visit: Plan for practical effects while waiting. Younger-onset disease often strains employment, income, childcare, and future-care choices. Get instructions in writing, name one contact for questions, and set a date to review results together.
- Ask if symptoms warrant Alzheimer's pathology testing now.
- Ask how APS2 would change the plan.
- Ask what follow-up test would confirm or refute the result.
- Ask who will explain results to work, family, or school supports.
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- The HHS National Alzheimer’s Plan Update for 2026-2035: Care-Planning Implications for Adult Children
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
